HRL
47
2
MOS
26
-3
VFC
74
3
GILD
52
2
TROW
58
5
HUM
36
7
CHD
34
2
BEN
49
13
EOG
45
3
SBUX
44
3
NWSA
64
4
ZION
61
4
URBN
72
-2
MPC
50
-4
BA
43
-2
MA
48
2
SE
47
-5
THC
60
-4
IR
63
-5
CINF
58
-2
HRL
47
2
MOS
26
-3
VFC
74
3
GILD
52
2
TROW
58
5
HUM
36
7
CHD
34
2
BEN
49
13
EOG
45
3
SBUX
44
3
NWSA
64
4
ZION
61
4
URBN
72
-2
MPC
50
-4
BA
43
-2
MA
48
2
SE
47
-5
THC
60
-4
IR
63
-5
CINF
58
-2
Financhill
Back

Apellis Pharmaceuticals, Inc. 10K Form

Sell
47

APLS
Apellis Pharmaceuticals, Inc.

Last Price:
$22.20
Seasonality Move:
12.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $781.4M
Cash Flow: $108.3M
Price / Cash Flow: 35.7
Annual Sales: $3.17
Price / Book: 7

Profitability

EPS (TTM): 0.29700
Net Income (TTM): $45M
Gross Margin: $663.6M
Return on Equity: 18.94%
Return on Assets: 5.03%

Apellis Pharmaceuticals, Inc. Earnings Forecast

Key Apellis Pharmaceuticals, Inc. Financial Ratios

  • The Gross Profit Margin over the past 7 years for APLS is 84.93%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 64.13% of Gross Profit Margin.
  • The Research & Development expenses have been 41.92% of Revenue.
  • The Net Earning history of APLS is -25.32% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 6 years.

Apellis Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 1.19
Current Ratio: 3.54
Quick Ratio: 2.96

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 2602.19

APLS Technical Analysis vs Fundamental Analysis

Sell
47
Apellis Pharmaceuticals, Inc. (APLS) is a Sell

Is Apellis Pharmaceuticals, Inc. a Buy or a Sell?